Mabsilico

MAbSilico is an AI-driven platform that accelerates therapeutic antibody discovery by designing high-affinity, epitope-specific humanized antibodies in 21 days.

Description

MAbSilico is an AI-powered web application platform designed to revolutionize therapeutic antibody discovery by accelerating and optimizing the process of designing high-quality antibody candidates. It leverages artificial intelligence for molecular docking and affinity prediction to create epitope-specific humanized antibodies with high efficacy and safety profiles. The platform integrates computational science, biology, and software development expertise to deliver fully characterized lead candidates in just 21 days, streamlining the transition from discovery to development. By evaluating factors like cross-reactivity, manufacturability, and sequence liabilities, MAbSilico ensures that the antibodies are not only effective but also stable and suitable for pre-clinical and clinical stages. This innovative approach aims to reduce the time, cost, and risk associated with traditional antibody discovery methods, enabling researchers to focus on advancing promising therapies faster.

Features

• AI-based docking and affinity prediction for precise antibody design on selected epitopes
• Evaluation of cross-reactivity and cross-specificity to minimize side effects and anticipate pre-clinical binding
• Assessment of manufacturability, including sequence liabilities like PTMs and aggregation motifs, to optimize stability and reduce immunogenicity
• Rapid lead candidate design with a turnaround time of 21 days
• Integration of computational science, biology, and software development expertise
• Focus on creating fully characterized, high-affinity antibodies ready for development

Benefits

• Widens pipeline by enabling faster and parallelized discovery programs
• Facilitates 'fail fast' approach to quickly identify and retry unsuccessful candidates
• Saves time and money by eliminating back-and-forth optimization of hits
• Enhances safety and efficacy through epitope-specific design and cross-reactivity evaluation
• Accelerates time-to-market for therapeutic antibodies by streamlining the discovery-to-development process

Links

• Home: https://www.mabsilico.com